 |
|
Anti-hypertensive drugs may help prevent and treat Alzheimer's disease
October 26, 2007A new study has identified commonly prescribed drugs for the treatment of hypertension may be capable of preventing Alzheimer�s disease and cognitive deterioration.
The new research, published in the November 2007 issue of the The Journal of Clinical Investigation., conducted by Dr. Giulio Maria Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Geriatrics and Adult Development and Director of the Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease at Mount Sinai School of Medicine, suggests that a large number of geriatric patients currently under pharmacological treatment for high-blood pressure with certain anti-hypertensive drugs might reap the additional benefits of the drug's cognitive effects.
"If we can deliver certain anti-hypertensive drugs to patients at high risk to develop Alzheimer�s disease, at doses that do not affect blood pressure, these drugs could be made available for all members of the geriatric population identified as being at high risk for developing Alzheimer's disease," said Dr. Pasinetti.
Study Results
Over the past two years, investigators directed by Dr. Pasinetti at Mount Sinai have been screening more than 1,500 drugs that are already commercially available for treatment of other disorders, to determine their potential value in treating Alzheimer's disease and cognitive impairment.
Based on the outcomes from initial drug screening, Dr. Pasinetti and his collaborators identified 7out of 55 candidate drugs commonly prescribed for the treatment of hypertension, which are capable of significantly preventing beta-amyloid production, which is a major mechanism recently identified as playing a key role in Alzheimer's disease pathogenesis, particularly in respect to promotion of memory loss and dementia. In this new study, Dr. Pasinetti reports that mice genetically determined to develop Alzheimer�s disease beta-amyloid production and subsequent cognitive deterioration, significantly benefit from the treatment with the anti-hypertensive agent Valsartan, found to pharmacologically prevent beta-amyloid production in the brain even when delivered to Alzheimer� disease mice at doses 3-4 fold lower than the minimal equivalent dose prescribed for the treatment of hypertension in humans. Other anti-hypertension drugs with beneficial results included Propranolol HCI, Carvedilol, Losartan, Nicardipine HCI, Amiloride HCI and Hydralazine HCI.
Showing the use of anti-hypertensive drugs with anti- beta-amyloid production activities in the brain of Alzheimer� disease mice, will help in the identification of future, novel disease- modifying pharmacological treatments for the prevention of cognitive deterioration and eventually dementia in Alzheimer's disease.
Future Research
Dr. Pasinetti recognizes the limitations of the research, noting that studies must be immediately verified in human subjects to verify the effect of the drugs on cognitive deterioration and memory functions independent of their role as an anti-hypertensive agent.
"The use of these drugs for their potential anti-Alzheimer�s disease role is still highly experimental, and at this stage we have no clinical data beyond phenomenological observation in humans" said Dr. Pasinetti. "We need to complete preventive and therapeutic clinical trials in the near future if we are to identify certain anti-hypertensive drugs with anti beta-amyloid antioligomeric activities, which will need to be prescribed at dosages that do not interfere with blood pressure in normotensive Alzheimer�s disease patients."
Dr. Pasinetti's research is part of a growing push to identify and develop more effective treatments for Alzheimer's disease. This devastating, degenerative illness is of particular concern for baby boomers beginning to turn 60, at increased risk of developing cognitive deterioration and Alzheimer's disease.
The Mount Sinai Hospital / Mount Sinai School of Medicine
Study Results
Over the past two years, investigators directed by Dr. Pasinetti at Mount Sinai have been screening more than 1,500 drugs that are already commercially available for treatment of other disorders, to determine their potential value in treating Alzheimer's disease and cognitive impairment.
Based on the outcomes from initial drug screening, Dr. Pasinetti and his collaborators identified 7out of 55 candidate drugs commonly prescribed for the treatment of hypertension, which are capable of significantly preventing beta-amyloid production, which is a major mechanism recently identified as playing a key role in Alzheimer's disease pathogenesis, particularly in respect to promotion of memory loss and dementia. In this new study, Dr. Pasinetti reports that mice genetically determined to develop Alzheimer�s disease beta-amyloid production and subsequent cognitive deterioration, significantly benefit from the treatment with the anti-hypertensive agent Valsartan, found to pharmacologically prevent beta-amyloid production in the brain even when delivered to Alzheimer� disease mice at doses 3-4 fold lower than the minimal equivalent dose prescribed for the treatment of hypertension in humans. Other anti-hypertension drugs with beneficial results included Propranolol HCI, Carvedilol, Losartan, Nicardipine HCI, Amiloride HCI and Hydralazine HCI.
Showing the use of anti-hypertensive drugs with anti- beta-amyloid production activities in the brain of Alzheimer� disease mice, will help in the identification of future, novel disease- modifying pharmacological treatments for the prevention of cognitive deterioration and eventually dementia in Alzheimer's disease.
Future Research
Dr. Pasinetti recognizes the limitations of the research, noting that studies must be immediately verified in human subjects to verify the effect of the drugs on cognitive deterioration and memory functions independent of their role as an anti-hypertensive agent.
"The use of these drugs for their potential anti-Alzheimer�s disease role is still highly experimental, and at this stage we have no clinical data beyond phenomenological observation in humans" said Dr. Pasinetti. "We need to complete preventive and therapeutic clinical trials in the near future if we are to identify certain anti-hypertensive drugs with anti beta-amyloid antioligomeric activities, which will need to be prescribed at dosages that do not interfere with blood pressure in normotensive Alzheimer�s disease patients."
Dr. Pasinetti's research is part of a growing push to identify and develop more effective treatments for Alzheimer's disease. This devastating, degenerative illness is of particular concern for baby boomers beginning to turn 60, at increased risk of developing cognitive deterioration and Alzheimer's disease.
The Mount Sinai Hospital / Mount Sinai School of Medicine
Anti-hypertensive Current Events and Anti-hypertensive News RSSAngiotensin receptor blockers are lower incidence, progression of Alzheimer's disease
Researchers at Boston University School of Medicine (BUSM) have, for the first time, found that angiotensin receptor blockers (ARBs)-a particular class of anti-hypertensive medicines-are associated with a striking decrease in the occurrence and progression of dementia. Data from this study will be presented this weekend (July 27) at the 2008 International Conference on Alzheimer's disease in Chicago.
Rheumatoid arthritis is a risk factor for cardiovascular disease
The risk of cardiovascular disease (CVD) for people with rheumatoid arthritis (RA) has been found to be comparable to the risk of CVD in people with type 2 diabetes.
Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors.
Microwave treatments for enlarged prostate cause blood pressure surges
Many men who receive microwave therapy for enlarged prostates experience significant surges in blood pressure that could raise their risk of a heart attack or stroke, according to new research findings published recently in Mayo Clinic Proceedings.
New guidelines issued for treating resistant hypertension
For the first time, the American Heart Association has issued guidelines to help patients and healthcare providers tackle resistant high blood pressure that seems to defy treatment.
Some hypertension drugs may help reduce dementia risk
Some high blood pressure medicines may help protect older adults from declines in memory and other cognitive function, according to new research from Wake Forest University School of Medicine.
Cocoa, but not tea, may lower blood pressure
Foods rich in cocoa appear to reduce blood pressure but drinking tea may not, according to an analysis of previously published research in the April 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Dual renin system blocking drug combo provides additional blood pressure-lowering effects
A combination of two medicines that act against the effects of the enzyme renin are more effective in lowering blood pressure than either of the medicines alone, according to a study presented today at the American College of Cardiology's 56th Annual Scientific Session.
Drug labels are prescriptions for mistakes
A new study to assess understanding of five common prescription label instructions found that patients had difficulty comprehending how much and how often the medication should be taken.
Nocturnal dialysis improves heart disease in patients with end-stage kidney failure
Night-time hemodialysis patients may have a greater capacity to repair their hearts and blood vessels compared to those on conventional dialysis three times a week.
More Anti-hypertensive Current Events and Anti-hypertensive News Articles
| © 2008 BrightSurf.com |